Announcements

Result of General Meeting

By July 10, 2015June 14th, 2016No Comments

Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that at the General Meeting held earlier today all resolutions as set out in the Notice of General Meeting annexed to the circular to shareholders dated 23 June 2015 were duly passed. The passing of the resolutions represents the satisfaction of the first of the two conditions to completion of the conditional placing of 44,000,000 ordinary shares announced by the Company on 23 June 2015.

The second condition, being the successful grant of the QIDP designation for iclaprim in the US (such grant not to be later than 24 July 2015), remains to be satisfied.

Enquiries

Motif Bio plc

Graham Lumsden, Chief Executive Officer
Robert Bertoldi, Chief Financial Officer
info@motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Dan Bate
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners (Broker)

Patrick Claridge
John Howes
+44 (0) 207 382 1100

Plumtree Capital Limited (Financial Advisor)

Stephen Austin
+44 (0) 207 183 2493

Yellow Jersey PR

Dominic Barretto
Philip Ranger
Fiona Walker
+44 (0) 7768 537 739

Notes to Editors

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.